Miscellaneous musculoskeletal disorders:
Indications for: KEVEYIS
Primary hyperkalemic or hypokalemic periodic paralysis and related variants.
Initially 50mg twice daily. Adjust dose based on response, at weekly intervals (or sooner if adverse reactions occur); max 200mg daily. Evaluate after 2 months.
Concomitant high-dose aspirin. Severe pulmonary disease. Hepatic insufficiency. Sulfonamides.
Discontinue at first sign of skin rash or immune-mediated or idiosyncratic adverse reaction. Adrenocortical insufficiency, hyperchloremic metabolic acidosis, respiratory acidosis: increased risk of hypokalemia. Metabolic acidosis. Monitor serum potassium and bicarbonate at baseline and periodically during treatment; reduce dose or discontinue if hypokalemia or metabolic acidosis develops. Increased risk of falls (esp. elderly, higher doses); consider dose reduction or discontinuation if occurs. Elderly. Pregnancy (Cat.C). Nursing mothers.
Carbonic anhydrase inhibitor.
Caution with concomitant low-dose aspirin. Increased risk of hypokalemia with loop or thiazide diuretics, laxatives, antifungals, penicillin, and theophylline.
Paresthesia, cognitive disorder, dysgeusia, confusion, hypoesthesia, lethargy, dizziness, nausea, fatigue, muscle spasms, rash; hypersensitivity reactions.
Half-life: 32-66 hours.
Generic Drug Availability: